Wall Street analysts expect Leap Therapeutics Inc (NASDAQ:LPTX) to report earnings of ($0.63) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Leap Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.62) and the lowest estimate coming in at ($0.63). Leap Therapeutics reported earnings of ($0.65) per share in the same quarter last year, which indicates a positive year over year growth rate of 3.1%. The business is expected to report its next quarterly earnings results on Friday, February 22nd.

On average, analysts expect that Leap Therapeutics will report full year earnings of ($2.37) per share for the current fiscal year, with EPS estimates ranging from ($2.39) to ($2.36). For the next fiscal year, analysts forecast that the company will report earnings of ($1.86) per share, with EPS estimates ranging from ($2.19) to ($1.57). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that follow Leap Therapeutics.

Leap Therapeutics (NASDAQ:LPTX) last issued its earnings results on Thursday, November 15th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02).

LPTX has been the subject of a number of recent research reports. Zacks Investment Research lowered Leap Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 26th. ValuEngine upgraded Leap Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 30th. Finally, HC Wainwright set a $13.00 price target on Leap Therapeutics and gave the company a “buy” rating in a research report on Tuesday, October 23rd.

A number of large investors have recently made changes to their positions in the business. Renaissance Technologies LLC grew its position in Leap Therapeutics by 23.5% in the third quarter. Renaissance Technologies LLC now owns 138,868 shares of the company’s stock valued at $1,082,000 after acquiring an additional 26,401 shares during the period. JPMorgan Chase & Co. bought a new stake in Leap Therapeutics in the third quarter valued at $111,000. Point72 Asset Management L.P. grew its position in Leap Therapeutics by 178.0% in the second quarter. Point72 Asset Management L.P. now owns 75,888 shares of the company’s stock valued at $683,000 after acquiring an additional 48,588 shares during the period. DRW Securities LLC bought a new stake in Leap Therapeutics in the second quarter valued at $347,000. Finally, Creative Planning bought a new stake in Leap Therapeutics in the second quarter valued at $144,000. Hedge funds and other institutional investors own 16.45% of the company’s stock.

Shares of NASDAQ LPTX traded down $0.10 during trading hours on Wednesday, reaching $3.70. The stock had a trading volume of 927 shares, compared to its average volume of 76,196. The firm has a market capitalization of $55.87 million, a price-to-earnings ratio of -1.13 and a beta of 2.11. Leap Therapeutics has a twelve month low of $3.46 and a twelve month high of $10.25.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.

Recommended Story: Price to Earnings Ratio (PE), For Valuing Stocks

Get a free copy of the Zacks research report on Leap Therapeutics (LPTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.